Last reviewed · How we verify
Benadryl demand
Benadryl (diphenhydramine) is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses.
Benadryl (diphenhydramine) is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses. Used for Allergic reactions and urticaria, Pruritus, Allergic rhinitis.
At a glance
| Generic name | Benadryl demand |
|---|---|
| Also known as | Diphenhydramine Hcl, Aler-Dryl, Banophen, Ben Tann, Bromanate AF |
| Sponsor | University of Pennsylvania |
| Drug class | First-generation H1 antihistamine |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Diphenhydramine competitively antagonizes H1 histamine receptors on various tissues, preventing histamine-mediated effects such as itching, urticaria, and allergic reactions. It also has anticholinergic properties that contribute to its sedating effects. The drug crosses the blood-brain barrier readily, which accounts for its central nervous system effects including drowsiness.
Approved indications
- Allergic reactions and urticaria
- Pruritus
- Allergic rhinitis
- Motion sickness and nausea
- Insomnia
Common side effects
- Drowsiness/sedation
- Dry mouth
- Dizziness
- Anticholinergic effects (urinary retention, constipation)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benadryl demand CI brief — competitive landscape report
- Benadryl demand updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI